GlassScriptPhysician profile
William R Davis
NPI 1790716165
$1,528.22
in general payments reported to CMS, 2019-2025
33 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $316 · 2021: $192 · 2022: $174 · 2023: $118 · 2024: $380 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594 · Travel and Lodging: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $593.82 |
| Travel and Lodging | $121.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $179.52 | 2019-2024 | |
| Amgen INC. | $170.59 | 2019-2025 | Repatha, Repatha |
| Lexicon Pharmaceuticals, INC. | $144.61 | 2023-2024 | Inpefa |
| Idorsia Pharmaceuticals US INC | $121.99 | 2024 | Cenerimod |
| Actelion Pharmaceuticals US, INC. | $121.95 | 2019-2023 | Opsumit |
| Zimmer Biomet Holdings, INC. | $112.56 | 2020 | |
| Esperion Therapeutics, INC. | $112.19 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $98.57 | 2022-2025 | |
| Heartflow, INC. | $50.96 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.99 | 2021 | |
| United Therapeutics Corporation | $44.25 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.72 | 2022 | |
| Inspire Medical Systems, INC. | $34.30 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $31.32 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $30.44 | 2020-2024 | Farxiga |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $27.57 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $24.94 | 2022 | |
| Lundbeck LLC | $19.67 | 2019 | |
| Medicomp INC | $19.65 | 2022 | |
| Amryt Pharma Holdings LTD | $18.84 | 2020 | |
| Philips North America LLC | $18.02 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.67 | 2024 | Camzyos |
| Medtronic, INC. | $16.49 | 2022 | |
| Elutia, INC. | $14.48 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $13.93 | 2019 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.